Combining postoperative radiotherapy and immunotherapy for advanced esophageal cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This pilot study aims to evaluate the safety and efficacy of combining postoperative radiotherapy with immunotherapy in patients who have undergone esophagectomy for locally advanced esophageal squamous cell carcinoma. A total of 70 patients will be enrolled and randomly assigned to either the experimental group receiving both treatments or the control group receiving only postoperative radiotherapy. The study will assess outcomes such as disease-free survival and potential side effects associated with the combined treatment approach. The trial is designed to provide insights into improving patient prognosis following surgery.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* 18-75 years old.
* After esophagectomy.
* Confirmation of squamous cell carcinoma by pathological examination.
* Pathological staging of pIIb-IVa.
* Over 12 lymph nodes dissected during surgery.
* ECOG 0-1.
* Signature of inform consent by patients

Exclusion Criteria:

* Younger than 18 years old or older than 75 years old.
* Without esophagectomy.
* Non-squamous cell carcinoma.
* Pathological staging of pI, IIa, IVb.
* Less than 12 lymph nodes dissected during surgery.
* ECOG 2-3 g. no signature of inform consent.

Where it's running

• Anhui Provicial Hospital
  Hefei, Anhui, China Recruiting

Study contacts

• Principal investigator: Dong Qian, M.D. — The First Affiliated Hospital of University of Science and Technology of China
• Study coordinator: Dong Qian, M.D.
• Email: qiandong@ustc.edu.cn
• Phone: +86-19156007756

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Paclitaxel given inside the abdomen with systemic therapy for GI cancers with peritoneal spread

  This phase II study tests a combination of intraperitoneal and systemic chemotherapy (paclitaxel) in adults with digestive tract cancers that have spread to the peritoneum.

  Recruiting Phase 2 University of California, Irvine · Orange, California · NCT07795749

• Impact of Surgical Treatment on Survival in Localized Small Cell Esophageal Cancer

  This study looks at whether surgery improves survival for people with localized small cell esophageal cancer compared with non-surgical treatment.

  Recruiting Jinling Hospital, China · Nanjing, Jiangsu · NCT07596654

• Postoperative Low Oxygen and Chance of Leaks After Esophageal Surgery

  This study looks at whether low oxygen levels after esophageal cancer surgery increase the chance of an anastomotic leak.

  Recruiting at 6 sites Sun Yat-sen University · Guangzhou, Guangdong and 5 other locations · NCT07309991

• Using the PAGODA algorithm to guide FOLFOX dose changes and reduce unplanned chemotherapy delays

  This trial will test whether using the PAGODA algorithm to guide dose changes during FOLFOX chemotherapy for people with gastrointestinal cancers can reduce unplanned treatment delays.

  Recruiting at 391 sites Alliance for Clinical Trials in Oncology · Fairbanks, Alaska and 397 other locations · NCT07283939

• Indocyanine green to highlight tumor depth and margins during endoscopic removal of esophageal or stomach cancer

  This trial will test whether a dye called indocyanine green can help doctors see the depth and edges of superficial esophageal or stomach cancers during endoscopic submucosal dissection.

  Recruiting Phase 1/2 University Medical Center Groningen · Groningen, Provincie Groningen · NCT07108855

• Best time for minimally invasive local treatment after first-line systemic therapy for limited (oligo) esophageal or stomach cancer

  This trial will test whether giving local treatment (surgery or radiation) earlier or later after first-line systemic therapy works better for people whose esophageal or stomach cancer has spread to only a few sites.

  Recruiting at 4 sites Phase 2 Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · Amsterdam and 4 other locations · NCT07000253

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.